Interestingly, accumulation of asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor, in the plasma of patients suffering from CKD[20,44], has been reported and proposed to contribute to endothelial dysfunction during fibrosis development[44], thereby confirming that NO plays a central role in fibrogenesis. The gene discussed is NOS1; the disease is chronic kidney disease.